Combination of lymphocyte count and albumin concentration as a new prognostic biomarker for rectal cancer

Yamamoto, Takehito; Kawada, Kenji; Hida, Koya; Matsusue, Ryo; Itatani, Yoshiro; Mizuno, Rei; Yamaguchi, Takashi; Ikai, Iwao; Sakai, Yoshiharu

doi:10.1038/s41598-021-84475-4

Cited by 26 publications

(24 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies reported that compared to normal albumin levels, patients with hypoalbuminemia had a lower 5-year survival rate (normal, 78% vs. hypoalbuminemia, 60%) and had lower 5-year recurrence-free rate or 5-years relapse-free survival than normal albumin level (normal, 78.9% vs. hypoalbuminemia, 73.5%). [17][18][19] This study also found a statistically significant association between CRP levels and NAC response. Elevated CRP is a secondary response to tumor necrosis, local tissue damage, and inflammation in malignancy patients.…”

Section: Original Articlesupporting

confidence: 73%

C-Reactive Protein (CRP)/Albumin Ratio (CAR) pre-treatment as a predictive factor of radiological response after neoadjuvant chemotherapy in Locally Advanced Rectal Cancer (LARC) patients at Dr. Soetomo General Hospital, Surabaya, Indonesia

Branko¹,

Lesmana²

2022

Bali Med J.

View full text Add to dashboard Cite

Background: Several serum inflammatory markers have been investigated as prognostic biomarkers for rectal cancer patients, including C-Reactive Protein (CRP)/Albumin Ratio (CAR). We aimed to examine the association between the CAR pre-therapy value and radiological response after neoadjuvant chemotherapyMethods: We recruited locally advanced rectal cancer patients who underwent FOLFOX first-line neoadjuvant chemotherapy (NAC) at Dr. Soetomo General Hospital (Surabaya, Indonesia) from January 2015 to December 2020. Before neoadjuvant chemotherapy treatment, the C-reactive protein (CRP) and albumin were measured. The chemotherapy response was performed by evaluating the CT scan result before and after the NAC was given. We used RESIST criteria to assess the radiological response after NAC treatment. Data were analyzed using SPSS version 23 for Windows.Results: We included a total of 102 patients, with the female being the predominant gender with LARC (52%.0). The well-differentiated adenocarcinoma was the most common adenocarcinoma type found in this study (59.8%). We found 57 patients with positive responses and 45 patients with negative responses. Patients with well-differentiated status who had adenocarcinoma had a higher chance to have a positive response to NAC. Patients with low CAR values had a 2.13 times higher chance of having a positive chemotherapy response than patients with high CAR values (95% CI = 1.30-3.30). Conclusion: There was a significant relationship between high CAR values and poor radiological response after neoadjuvant chemotherapy in locally advanced rectal cancer patients. The CAR value may be a potential biomarker to predict the radiologic response after NAC treatment.

show abstract

Section: Original Articlesupporting

confidence: 73%

C-Reactive Protein (CRP)/Albumin Ratio (CAR) pre-treatment as a predictive factor of radiological response after neoadjuvant chemotherapy in Locally Advanced Rectal Cancer (LARC) patients at Dr. Soetomo General Hospital, Surabaya, Indonesia

Branko¹,

Lesmana²

2022

Bali Med J.

View full text Add to dashboard Cite

show abstract

“…We have recently reported the novel prognostic marker “LA”, which means “lymphocyte count × albumin level (g/dL) [ 2 ]. We retrospectively collected data from a total of 448 rectal cancer patients (Stage II and III) from two large centers, and found that low LA (≤5950) was independently associated with both OS and RFS.…”

Section: Albumin-related Markersmentioning

confidence: 99%

“…Previously, we reported that the combination of GPS and NLR could effectively predict the prognosis of CRC patients who underwent curative resection [ 1 ]. In addition, we focused on rectal cancer patients (Stage II and III) and showed that the combination of circulating lymphocyte count and serum albumin concentration could be a useful predictor for prognosis [ 2 ]. However, there are many other inflammation-related biomarkers investigated regarding CRC.…”

Section: Introductionmentioning

confidence: 99%

Inflammation-Related Biomarkers for the Prediction of Prognosis in Colorectal Cancer Patients

Yamamoto

Kawada

Obama

2021

IJMS

Self Cite

217

140

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the leading cause of cancer deaths around the world. It is necessary to identify patients with poor prognosis or with high risk for recurrence so that we can selectively perform intensive treatments such as preoperative and/or postoperative chemotherapy and extended surgery. The clinical usefulness of inflammation-related prognostic biomarkers available from routine blood examination has been reported in many types of cancer, e.g., neutrophil–lymphocyte ratio (NLR), lymphocyte–C-reactive protein ratio (LCR), platelet–lymphocyte ratio (PLR), lymphocyte–monocyte ratio (LMR), and so on. Moreover, some scoring systems based on circulating blood cell counts and albumin concentration have been also reported to predict cancer patients’ prognosis, such as the Glasgow prognostic score (GPS), systemic inflammation score (SIS), and prognostic nutritional index (PNI). The optimal biomarker and optimal cutoff value of the markers can be different depending on the cancer type. In this review, we summarize the prognostic impact of each inflammation-related marker in CRC.

show abstract

“…There are many studies on the relationship between albumin and the prognosis of solid tumors. (29)(30)(31). The albumin level is also associated with the prognosis of esophageal cancer (32,33).…”

Section: Discussionmentioning

confidence: 99%

A clinical nomogram for predicting tumor regression grade in esophageal squamous-cell carcinoma treated with immune neoadjuvant immunotherapy

Yu¹,

Wang²,

Qin³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

Background: There are various treatment options for esophageal squamous cell cancer. including surgery, peri-operative chemotherapy, and radiation. More recently, neoadjuvant immunotherapy has also been shown improve outcomes. In this study, we addressed the question, "Can we predict which patients with esophageal squamous cell cancer will benefit from neoadjuvant immunotherapy?". Methods: All patients with thoracic esophageal squamous-cell carcinoma (T2N+M0-T3-4N0/+M0) (according to the eighth edition of the National Comprehensive Cancer Network guidelines) who underwent immune neoadjuvant immunochemotherapy with programmed cell death protein 1 (PD-1) combined with paclitaxel plus cisplatin or nedaplatin in the Affiliated Cancer Hospital of Zhengzhou University, China, between November 2019 and August 2021 were included in this study. All patients underwent surgical resection. We developed a response [tumor regression grade (TRG)] prediction model using the least absolute shrinkage and selection operator (LASSO) regression incorporating factors associated with response. The accuracy of the prediction model was then validated.Results: We included 79 patients who underwent neoadjuvant immunotherapy combined with chemotherapy, aged 48-78 years (62.05±6.67), including 21 males and 58 females. There were five cases of immune-related pneumonia, of which three cases were diagnosed as immune-related pneumonia during the perioperative period, and one case of immune-related thyroid dysfunction changes. After LASSO regression, the factors that were independently associated with TRG were clinical T stage before neoadjuvant therapy, clinical N stage before neoadjuvant therapy, albumin level difference from before to after neoadjuvant therapy, white blood cell (WBC) count before neoadjuvant therapy, and T stage before surgery. We constructed a prediction model, plotted the nomogram, and verified its accuracy. Its Brier score was 0.13, its calibration slope was 0.98, and its C-index was 0.90 (95% CI: 0.82-0.97).Conclusions: Our prediction model can predict the likelihood of TRG in patients with esophageal squamous cell cancer after immunotherapy combined with neoadjuvant chemotherapy. Using this prediction model, we plan to conduct a subsequent neoadjuvant radiotherapy in patients with of TRG 2-3 patients with neoadjuvant radiotherapy.

show abstract

Combination of lymphocyte count and albumin concentration as a new prognostic biomarker for rectal cancer

Cited by 26 publications

References 26 publications

C-Reactive Protein (CRP)/Albumin Ratio (CAR) pre-treatment as a predictive factor of radiological response after neoadjuvant chemotherapy in Locally Advanced Rectal Cancer (LARC) patients at Dr. Soetomo General Hospital, Surabaya, Indonesia

C-Reactive Protein (CRP)/Albumin Ratio (CAR) pre-treatment as a predictive factor of radiological response after neoadjuvant chemotherapy in Locally Advanced Rectal Cancer (LARC) patients at Dr. Soetomo General Hospital, Surabaya, Indonesia

Inflammation-Related Biomarkers for the Prediction of Prognosis in Colorectal Cancer Patients

A clinical nomogram for predicting tumor regression grade in esophageal squamous-cell carcinoma treated with immune neoadjuvant immunotherapy

Contact Info

Product

Resources

About